Can Ursodeoxycholic Acid Prevent SARS-CoV-2 Infection or Reduce the COVID-19 Severity? Current Knowledge and Unresolved Issues  

作　　者：Shida Pan Yang Zhang Fanping Meng Fu-Sheng Wang 

机构地区：[1]Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [2]Department of Infectious Diseases,The Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China

出　　处：《Infectious Diseases & Immunity》2023年第3期114-119,共6页感染性疾病与免疫（英文）

基　　金：Innovation Groups of the National Natural Science Foundation of China(81721002);National Key R&D Program of China(2020YFC0860900)。

摘　　要：A recent study revealed that the inhibition of the farnesoid X receptor using ursodeoxycholic acid(UDCA)significantly reduces angiotensin-converting enzyme 2(ACE2)expression.Therefore,considerable attention has been paid to the use of UDCA to prevent severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and reduce the severity of the disease.This review compre-hensively summarizes the role of ACE2 in SARS-CoV-2 infection and the potential role and mechanisms of UDCA in the prevention of SARS-CoV-2 infection or reinfection.It also discusses unresolved issues and the potential use of UDCA in the treatment of patients with coronavirus disease.

关 键 词：COVID-19 SARS-CoV-2 Prevention Ursodeoxycholic acid REINFECTION 

分 类 号：R563.1[医药卫生—呼吸系统]